Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | MELK | Q14680 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 3/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1266812 | 0.98 | CYP1A2 (0.42) | CYP1A2CYP2D6CHRNB2CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL2315581 | 0.95 | CYP1A2 (0.41) | CYP1A2CYP2D6CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL22638762 | 0.82 | CYP2D6 (0.49) | CYP1A2CYP2D6MELKASIC3 | |
| SCHEMBL330372 | 0.82 | ASIC3 (0.60) | HTR2AHTR2CMELKPNMTADRA2A | |
| SCHEMBL420370 | 0.82 | PNMT (0.60) | HTR2AHTR2CMELKPNMTADRA2A | |
| SCHEMBL29386484 | 0.82 | CYP2D6 (0.49) | CYP1A2CYP2D6MELKASIC3 | |
| SCHEMBL29741628 | 0.82 | PNMT (0.60) | HTR2AHTR2CMELKPNMTADRA2A | |
| SCHEMBL31468751 | 0.81 | PARP1 (0.36) | CYP1A2CYP2D6CHRNB2CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL1000880 | 0.81 | ASIC3 (0.58) | HTR2AHTR2CMELKPNMTADRA2A | |
| Hydrochloric Acid SCHEMBL29586555 | 0.81 | PNMT (0.58) | HTR2AHTR2CMELKPNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624024-B2 | EP2 antagonist compounds | RESERVOIR NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4680612-A1 | CHEMICAL COMPOUNDS | AN2 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250263394-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | INVENTISBIO LLC | 2025-08-21 | — | — | US | disclosed |
| US-20250206752-A1 | PI3K INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-119948023-A | Regulator containing piperidine polycyclic derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-12281122-B1 | PI3K inhibitors | COGENT BIOSCIENCES, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2025051216-A1 | CYP11A1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳众格生物科技有限公司 | 2025-03-13 | — | — | WO | disclosed |
| WO-2025040167-A1 | PHOSPHOINOSITIDE 3-KINASE ALLOSTERIC INHIBITOR FOR TREATING DISEASE RELATED TO PI3K REGULATION | 上海艾力斯医药科技股份有限公司 | 2025-02-27 | — | — | WO | disclosed |
| WO-2025029683-A1 | PI3K INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| EP-1595866-A1 | COMPOUND INHIBITING DIPEPTIDYL PEPTIDASE IV | Sanwa Kagaku Kenkyusho Co., Ltd. (JP) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-1554243-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004037788-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| US-5869518-A | USEFUL IN THE TREATMENT OF OBESITY AND HYPERGLYCEMIA | SYNTHELABO (FR) | 1999-02-09 | — | — | US | disclosed |
| CN-1188478-A | Azacycloalcane derivatives, preparation thereof and their applications in therapy | SYNTHELABO (FR) | 1998-07-22 | — | — | CN | disclosed |
| EP-0823912-A1 | AZACYCLOALCANE DERIVATIVES, PREPARATION THEREOF AND THEIR APPLICATIONS IN THERAPY | SYNTHELABO (FR) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996034870-A1 | AZACYCLOALCANE DERIVATIVES, PREPARATION THEREOF AND THEIR APPLICATIONS IN THERAPY | SYNTHELABO (FR) | 1996-11-07 | — | — | WO | disclosed |
| US-5026856-A | Bactericides | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1991-06-25 | — | — | US | disclosed |
| EP-0343560-A2 | Isoindoline derivative | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263394-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | PIK3CD, PIK3CA, PIK3C2B | CYP1A2 3807/4885CYP2D6 2557/4885CHRNB2 4788/4885 |
| US-20250206752-A1 | PI3K INHIBITORS | PIK3CA, PIK3R5, PIK3R4 | CYP1A2 2039/4885CYP2D6 3496/4885CHRNB2 4329/4885 |
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | CYP1A2 3561/4885CYP2D6 3877/4885CHRNB2 4752/4885 |
| US-12281122-B1 | PI3K inhibitors | PIK3CA, PIK3R5, PIK3R4 | CYP1A2 2039/4885CYP2D6 3496/4885CHRNB2 4329/4885 |
| US-12624024-B2 | EP2 antagonist compounds | PTGER1, PTGER2, PTGER4 | CYP1A2 405/4885CYP2D6 377/4885CHRNB2 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.